ReviewNature reviews. Immunology2011
The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.
Review in Nature reviews. Immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Cervicovaginal Tissue Residence Confers a Distinct Differentiation Program upon Memory CD8 T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Review
- New prospects for a preventive HIV-1 vaccine.Journal of virus eradication · 2015Article
- Recent developments in clinical trial designs for HIV vaccine research.Human vaccines & immunotherapeutics · 2015Review
- Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.Journal of virology · 2014Article
- Article
- Human immunodeficiency virus vaccine trials.Cold Spring Harbor perspectives in medicine · 2012Review
- HIV-1 dynamics: a reappraisal of host and viral factors, as well as methodological issues.Viruses · 2012Review
- Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Retrovirology · 2012Review
- Measurements of immune responses for establishing correlates of vaccine protection against HIV.AIDS research and human retroviruses · 2012Article
- The design and evaluation of HIV-1 vaccines.AIDS (London, England) · 2012Review
- Evolutionary dynamics of HIV at multiple spatial and temporal scales.Journal of molecular medicine (Berlin, Germany) · 2012Review
- The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization.PloS one · 2012Article
- Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.PloS one · 2012Article
- Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS.PLoS pathogens · 2012Article
- Basic research in HIV vaccinology is hampered by reductionist thinking.Frontiers in immunology · 2012Article
- Article
- HIV-1 Vaccine Trials: Evolving Concepts and Designs.The open AIDS journal · 2012Article
- Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.Nature reviews. Cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Even before the partial success of a preventive HIV vaccine in a recent Phase III clinical trial, there had been an active research effort to determine one or more immune correlates of protection for HIV infection. This effort has been hampered by the lack of natural protective immunity against HIV. As a result, most of the studies have focused on long-term non-progressive infection or other clinical situations, none of which fully recapitulates protective immunity against HIV. Although this effort has been successful in defining characteristics of T cells in acute and non-progressive HIV infection, and has therefore greatly expanded our knowledge of the immunopathogenesis of AIDS, its success in defining immune correlates of protection is less clear. In this Opinion article we offer a perspective on how successful this effort has been in defining immune correlates of protection that have been, or will be, of use in the development of an HIV vaccine. Our view is that investing in an iterative approach to human vaccine efficacy trials of sufficient size and sampling frequency will improve the likelihood that an immune correlate of vaccine protection will be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.